Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE)

Amendment 2: Changes to the ISO

The purpose of this amendment is to amend the THRIVE ISO. An updated version of the ISO and an updated version of the ISO with tracked changes are included as attachments. Changes to the ISO include:

1. Cost share is now strongly encouraged instead of mandatory.


2. Multi-party teaming arrangements are no longer required.


3. ARPA-H's involvement with regulatory facilitation has been clarified.

Please review the amended ISO for all changes.

----------------------------------------------------------------------------------------------------------------

Amendment 1: Added the Frequently Asked Questions (FAQ) to the list of attachments.

----------------------------------------------------------------------------------------------------------------

The Advanced Research Projects Agency for Health (ARPA-H) Treating Hereditary Rare diseases with In Vivo precision genetic mEdicines (THRIVE) program envisions a future where patients can opt for one-time therapeutic interventions designed to slow, reverse, or cure disease, harnessing revolutionary technologies and a rapidly evolving understanding of the genetic underpinnings of the biological processes that lead to disease.

Interested parties are invited to review the attached THRIVE Innovative Solutions Opening (ISO) ARPA-H -SOL-25-122.

For detailed information regarding Proposers' Day review Special Notice (SN) ARPA-H-SN-25-131.

Solution summaries are due October 31, 2025, 11:59 PM ET.

For more information about THRIVE, please visit:https://arpa-h.gov/explore-funding/programs/thrive